Immuneering Corporation IMRX
3.79 USD -0.06 (-1.56%)
At closeNov 11, 2026, 7:50 PM EST
3.85 +0.06 +1.58%
After hours · Nov 11, 7:50 PM ET
3.79 Day range 3.95
3.37 52-week range 8.33
- YTD
- -42.40%
- 1 year
- -43.77%
News
globenewswire.com Immuneering Appoints Accomplished Commercial Leader Grant Bogle to Board of Directors - Former TESARO Chief Commercial Officer and Nuvalent board member brings extensive experience in oncology product launches and commercial strategy - - Led commercialization of ZEJULA for ovarian…
benzinga.com Immuneering Announces Its Atebimetinib's Data Shows Improvement In Activity Of PD-1 Checkpoint Blockade In RAS-Mutant Colorectal And Lung Cancer Models; Demonstrates 50% Durable Complete Regression In Colorectal Model Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced compelling preclinical data…
globenewswire.com Atebimetinib Combinations with Anti-PD1 Cured 50% of Mice in a RAS-Mutant Colorectal Cancer Model and Nearly Doubled Survival in a RAS-Mutant Lung Cancer Model; New Data Presented at SITC 2026 - Durable complete regressions observed in 50% of mice in a RAS-mutant colorectal cancer model treated with Atebimetinib plus anti-PD-1, with no regrowth even after dosing stopped - - Median survival…
globenewswire.com Immuneering to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today…
globenewswire.com Immuneering to Highlight Atebimetinib's Broad Potential for Combinations in Pancreatic and Anaplastic Thyroid Cancers at the 2026 EORTC-NCI-AACR Symposium Immuneering to Highlight Atebimetinib's Broad Potential for Combinations in Pancreatic and Anaplastic Thyroid Cancers at the 2026 EORTC-NCI-AACR Symposium
globenewswire.com Immuneering Reports Third Quarter 2026 Financial Results and Provides Business Updates - Phase 2 pancreatic cancer follow-up extended as patients on atebimetinib combinations live longer than projected - - Updated Phase 2 atebimetinib + mGnP pancreatic cancer data (N=55) expected in…
globenewswire.com Immuneering Presents Design and Methodology of Ongoing Phase 3 MAPKeeper 301 Trial at ESMO Congress 2026 - Ongoing Pivotal Phase 3 trial evaluating atebimetinib in combination with modified gemcitabine/nab-paclitaxel versus standard-of-care chemotherapy in first-line metastatic pancreatic cancer -…
globenewswire.com Immuneering to Present at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC) - Atebimetinib enhances PD-1 checkpoint blockade in preclinical models of RAS mutant tumors - - Findings provide additional mechanistic rationale for upcoming Phase 2 study of atebimetinib in…
globenewswire.com Immuneering Presents Data at 2026 AACR Conference on Pancreatic Cancer Supporting Atebimetinib's Mechanisms Designed to Extend Survival in Pancreatic Cancer - Stable or increased weight was twice as common among pancreatic cancer patients in the atebimetinib + mGnP study, compared to those in a benchmark study -
globenewswire.com Immuneering to Present at the ESMO Congress 2026 NEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today…
defenseworld.net Squarepoint Ops LLC Has $288,000 Holdings in Immuneering Corporation $IMRX Squarepoint Ops LLC decreased its position in shares of Immuneering Corporation (NASDAQ: IMRX) by 74.5% in the undefined quarter, according to the company in its most recent Form 13F filing with the…
benzinga.com Immuneering To Present Data At American Association For Cancer Research Conference On Pancreatic Cancer: New Frontiers In Biology And Therapeutic Development Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced it will present a poster at the…
globenewswire.com Immuneering to Present at the AACR Conference on Pancreatic Cancer, Highlighting Atebimetinib's Dual Mechanism for Extended Survival - Expands on previously reported findings in which 84% of evaluable first-line PDAC patients treated with atebimetinib + mGnP maintained or gained weight at three months - - New analyses evaluate the…
globenewswire.com Immuneering to Participate in Upcoming Investor Conferences NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today…
benzinga.com Immuneering Highlights Atebimetinib’s Potential In 1L Metastatic Pancreatic Cancer As FDA Approves New 2L Treatment - For patients with second-line (2L) metastatic pancreatic cancer, today’s FDA approval of a new treatment is an important milestone – - For patients with first-line (1L) metastatic pancreatic…
globenewswire.com Immuneering Comments on Today's FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients - For patients with second-line (2L) metastatic pancreatic cancer, today's FDA approval of a new treatment is an important milestone – - For patients with first-line (1L) metastatic pancreatic…
benzinga.com This Lyell Immunopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday Wall Street analysts change outlook on top names. Check analyst ratings page for all changes. See what analysts say about LYEL, IMRX, and RNA.
247wallst.com Here Are Thursday’s Top Wall Street Analyst Research Calls: AppLovin, Charles River, Global Payments, HubSpot, Insulet Corporation, Roper Technologies, Sabra Health Care, Western Digital, Zillow Group, and More Wall Street analysts made some dramatic moves on Thursday, slashing price targets by double digits on several high-profile names while upgrading others to buy. Find out which stocks got the most…- benzinga.com HC Wainwright & Co. Initiates Coverage On Immuneering with Buy Rating, Announces Price Target of $14 HC Wainwright & Co. analyst Andres Y. Maldonado initiates coverage on Immuneering (NASDAQ:IMRX) with a Buy rating and announces Price Target of $14.
benzinga.com Immuneering Q2 EPS $(0.27), Inline Immuneering (NASDAQ:IMRX) reported quarterly losses of $(0.27) per share which met the analyst consensus estimate. This is a 32.5 percent increase over losses of $(0.40) per share from the same…
globenewswire.com Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates - 17.3 month median overall survival in 55 first-line pancreatic cancer patients treated with atebimetinib in combination with chemotherapy, reported in oral presentation at ASCO Annual Meeting on…
seekingalpha.com Immuneering: A Third (Much Cheaper) Way To Invest In The RAS-RAF-MEK-ERK 'Revolution' Immuneering Corporation targets first-line pancreatic cancer with atebimetinib, showing promising Phase 2a results versus standard-of-care regimens. IMRX's pivotal Phase 3 trial in first-line PDAC is…- benzinga.com Immuneering Publishes New Findings In Cancer Research Characterizing The Differentiated Mechanism And Broad Preclinical Activity Of Atebimetinib; Atebimetinib Showed Broad Antitumor Activity Across KRAS-, NRAS-, And BRAF-mutant Models, Including Colorectal, Lung, And Melanoma, By Resisting The RAF-Mediated Bypass Signaling That Has Constrained Other MEK Inhibitors - Atebimetinib showed broad antitumor activity across KRAS-, NRAS-, and BRAF-mutant models, including colorectal, lung, and melanoma, by resisting the RAF-mediated bypass signaling that has…
globenewswire.com Publication in Cancer Research Details Atebimetinib's Broad, Durable Preclinical Activity and Favorable Tolerability Across RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition - Atebimetinib showed broad antitumor activity across KRAS-, NRAS-, and BRAF-mutant models, including colorectal, lung, and melanoma, by resisting the RAF-mediated bypass signaling that has…
benzinga.com Needham Maintains Buy on Immuneering, Raises Price Target to $18 Needham analyst Ami Fadia maintains Immuneering (NASDAQ:IMRX) with a Buy and raises the price target from $11 to $18.
globenewswire.com Immuneering Corporation Announces Grants of Inducement Awards NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, previously…
zacks.com Immuneering (IMRX) Upgraded to Buy: Here's What You Should Know Immuneering (IMRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
benzinga.com Immuneering Appoints Andrew Gengos CFO, Effective July 16 Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced the appointment of Andrew Gengos as…
benzinga.com Immuneering Doses First Patient In MAPKeeper 301 Pivotal Phase 3 Clinical Study Of Atebimetinib Plus Modified Gemcitabine/Nab-Paclitaxel To Treat Metastatic Pancreatic Cancer Patients Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that the first patient has been dosed…
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session - benzinga.com Immuneering Announces Updated Clinical Data From Ongoing Phase 2a Trial Evaluating Atebimetinib In Combination With mGnP In First-Line Metastatic Pancreatic Ductal Adenocarcinoma - 17.3 months median overall survival in 55 first-line pancreatic cancer patients; vs. 8.5 months for standard of care chemotherapy in the pivotal MPACT study -- Only two categories of Grade 3+…
benzinga.com Crude Oil Edges Higher; US Consumer Sentiment Falls In May US stocks rose, Dow gained over 400 points. S&P 500 and NASDAQ also up. Health care shares jumped, while communication services fell. University of Michigan's consumer sentiment index hit record low.…
benzinga.com Zoom Upbeat Q1 Results, Joins Lionsgate Studios, Ross Stores And Other Big Stocks Moving Higher On Friday Zoom Communications Inc shares rise after strong financial results and increased buyback authorization. Other big gainers include IMRX, INFQ, ASMB, IMAX, RGTI, HLIT, DELL, EL, GSIT, ELVR, and HPQ.- benzinga.com Immuneering Reveals 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy; Tolerability Profile Consistent With Prior Updates; Only Two Categories Of Grade 3 Or Higher Treatment-Related Adverse Events Observed In ≥10% Of Patients, Both Chemotherapy-Related Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today reported a 17.3-month median overall survival…
benzinga.com Immuneering Q1 EPS $(0.21) Beats $(0.26) Estimate Immuneering (NASDAQ:IMRX) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.26) by 19.23 percent. This is a 50 percent increase over losses of $(0.42)…
benzinga.com Immuneering To Present Updated Data From Phase 2a Clinical Trial Evaluating Atebimetinib In Combination With mGnP In First-Line Pancreatic Cancer At 2026 ASCO Annual Meeting - New data from Phase 2a clinical trial evaluating atebimetinib + mGnP in first-line pancreatic cancer will be presented in an oral session by Dr. Peter Vu, UC San Diego Health -- The ASCO…- benzinga.com Immuneering To Present Atebimetinib ctDNA Data Showing Durable Tumor Shrinkage At AACR 2026 Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced it will present a poster on one of the…
- benzinga.com Immuneering Q4 EPS $(0.18) Beats $(0.31) Estimate Immuneering (NASDAQ:IMRX) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.31) by 42.31 percent. This is a 68.97 percent increase over losses of $(0.58)…
benzinga.com Looking Into Immuneering Corp's Recent Short Interest 
benzinga.com Benzinga Bulls And Bears: Chevron, Palantir, Aquestive — And Real Estate Stocks Plummet Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.
benzinga.com Dow Jumps Over 250 Points; US Initial Jobless Claims Increase - benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
benzinga.com Nasdaq Falls Over 100 Points; Acuity Posts Upbeat Earnings 
benzinga.com Immuneering Pancreatic Cancer Trial Touts Encouraging Survival Data, But Stock Moves Lower Immuneering shares traded lower after new pancreatic cancer trial data showed improved survival, manageable safety, and key trial milestones expected in 2026.
benzinga.com Stock Market Today: S&P 500, Dow Jones, Nasdaq 100 Futures Drop— AZZ, Northrop Grumman, Immuneering In Focus (UPDATED) (Editor’s note: The future prices of benchmark tracking ETFs and the headline were updated in the story.) U.S. stock futures declined on Thursday following a mixed close on Tuesday, with only the…
benzinga.com Immuneering, Phathom Pharmaceuticals, Canadian Solar And Other Big Stocks Moving Lower In Thursday's Pre-Market Session 
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session 
benzinga.com Why AZZ Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket 
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session - benzinga.com Immuneering Reports Updated Overall Survival And Safety Data From Its Ongoing Phase 2a Trial Of Atebimetinib In Combination With Modified Gemcitabine/Nab-Paclitaxel In First-line Pancreatic Cancer Patients With Over 13 Months Median Follow Up Time; Atebimetinib Consistently Demonstrates Overall Survival Advantage At All Time Periods Reported; Median Overall Survival Remains Unreached As Of Data Cutoff Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced positive updated overall survival (OS)…